CliffBio
small molecule

PRESTALIA

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

Loss of exclusivityOctober 2029latest FDA-listed patent expiry
CompanyAdhera Therapeutics →View the full company profile on CliffBio

Drug detail

Brand namePRESTALIA
Active ingredientAMLODIPINE BESYLATE; PERINDOPRIL ARGININE
StrengthEQ 5MG BASE;7MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2015
Marketing statusDISCN

Listed patents

PatentExpiresType
7846961October 2029substance, product

More from Adhera Therapeutics

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

PRESTALIA patent cliff — loss of exclusivity October 2029 | CliffBio